This concept led to the KRYSTAL-1 trial, a phase 1-2 open label non-randomized trial of patients with pre-treated KRAS G12C mutated CRC in which patients were provided adagrasib, an oral small molecule inhibitor of KRAS G12C protein in combination with cetuximab or adagrasib monotherapy (Table 1). This evidence concerns the gene KRAS and colorectal carcinoma.